Influence of the NIH Consensus Conference on Helicobacter Pylori on Physician Prescribing among a Medicaid Population

Medical Care

Volumn 36, Issue 5, 1998, Pages 646-660

  Thamer, Mae ^a,d   Ray, Nancy Fox ^a,b   Henderson, Scott C ^a   Rinehart, Cheryl S ^a   Sherman, Charles R ^c   Ferguson, John H ^c  

^a Med Technol Pract Patterns Inst   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Medical Technology & Practice Patterns Institute   (United States)

Author keywords

Antibiotics; Antimicrobials; H. pylori; Medicaid population; NIH Consensus Development Conference; Omeprazole; Peptic ulcer disease; Physician prescribing

Indexed keywords

ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; DRUG ANTAGONISM; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MEDICAID; MICROBIOLOGY; MIDDLE AGED; PEPTIC ULCER; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICS; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COHORT STUDIES; CONSENSUS DEVELOPMENT CONFERENCES, NIH; FEMALE; GUIDELINE ADHERENCE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MEDICAID; MIDDLE AGED; OMEPRAZOLE; PENNSYLVANIA; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROTON PUMPS; UNITED STATES;

EID: 0032066646     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199805000-00005     Document Type: Article

References (70)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65.
2. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 1996;86:200.
3. National Digestive Diseases Information Clearinghouse. Digestive Disease Statistics, February 1995.
4. Wormsley KG. Campylobacter pylori and ulcer disease: A causal connection? Scand J Gastroenterol 1989;160:53.
5. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991;324:1043.
6. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991;13:42.
7. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992;102:720.
8. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984.
9. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA 1994;271:808.
10. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977.
11. Fendrick AM, Chernew ME, Hirth RA, et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995;123:260.
12. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992;116:705.
13. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: A randomized controlled trial. Ann Intern Med 1991;115:266.
14. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233.
15. Coghlan JG, Gilligan D, Humphreys H, et al. Campylobacter pylori and recurrence of duodenal ulcers: A 12 month follow-up study. Lancet 1987;2:1109.
16. Soll AH. Medical treatment of peptic ulcer disease: Practice guidelines. JAMA 1996;275:622.
17. Hirth RA, Fendrick AM, Chernew ME. Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care 1996;34:1199.
18. Roll J, Weng A, Newman J. Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients. Arch Intern Med 1997;157:994.
19. Munnangi S, Sonnenberg A. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med 1997;157:1489.
20. Agresti A. Categorical data analysis. New York: John Wiley and Sons, 1990.
21. Woodfield T. Time series intervention analysis using SAS software. Proceedings of the Twelfth Annual SAS Users Group International Conference, February 8-11, 1987, Dallas, Texas. Cary, NC: SAS Institute, 1987:331.
22. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: An example to evaluate regionalized perinatal care. Am J Pub Health 1981;71:38.
23. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612.
24. Bendahan J, Gilboa S, Paran H, et al. Seasonal pattern in the incidence of bleeding caused by peptic ulcer in Israel. Am J Gastroenterol 1992;87:733.
25. Hall WH, Read RC, Mesard L, et al. The calendar and duodenal ulcer. Gastroenterology 1972;62:1120.
26. SAS Institute. SAS/ETS user's guide. Version 6, 2nd edition. Cary, NC: SAS Institute, 1993.
27. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;331:717.
28. Soil AH, Weinstein WM, Kurata J, et al. Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307.
29. Green L, Kreuter M, Deeds S, Partridge K. Health education planning: A diagnostic approach. Palo Alto, CA: Mayfield Press, 1980.
30. Kosecoff J, Kanouse DE, Rogers WH, et al. Effects of the National Institutes of Health consensus development program on physician practice. JAMA 1987;258:2708.
31. Wortman PM, Vinokur A, Sechrest L. Do consensus conferences work? A process evaluation of the NIH consensus development program. J Health Polit Policy Law 1988;13:469.
32. Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations. Ann Rev Pub Health 1991;12:41.
33. Sherman CR, Potosky AL, Weis KA, et al. The consensus development program: Detecting changes in medical practice following a consensus conference on the treatment of prostate cancer. Int J Technol Assess Health Care 1992;8:683
34. Kosecoff J, Kanouse DE, Brook RH. Changing the practice patterns in the management of primary breast cancer: Consensus development program. Health Serv Res 1990;20:809.
35. Kanouse DE, Brook RH, Winkler JD, et al. Changing medical practice through technology assessment an evaluation of the National Institutes of Health Consensus Development Program. Santa Monica, CA: The Rand Corporation, 1989.
36. Guidelines for doctors in the new world. Lancet 1992;339:1197. Editorial.
37. Evans RW, Mannienen DL, Dong FB. An economic analysis of liver transplantation. Gastroenterol Clin N Amer 1993;22:451.
38. American College of Obstetricians and Gynecologists Committee on Obstetrics: Maternal and Fetal Medicine. Guidelines for vaginal delivery after a Cesarean childbirth. Washington, DC: American College of Obstetricians and Gynecologists, 1982.
39. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996;91:239.
40. P & G and Quidel to promote H. pylori duodenal ulcer products to physicians. PR Newswire [Online].Website http://www.prnewswire.com Jan 14, 1997.
41. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4.
42. Stein LS. The effectiveness of continuing medical education: Eight research reports. J Med Educ 1981;56:103.
43. Pinkerton RE, Tinanoff N, Willms JL, et al. Resident physician performance in a continuing education format. JAMA 1980;244:2183.
44. Avorn J, Soumerai SB. Improving drug therapy decisions through educational outreach: A randomized controlled trial of academically based "detailing." N Engl J Med 1983;308:1457.
45. F-D-C Reports. The Pink Sheet. 1994 Nov 7;9.
46. F-D-C Reports. The Pink Sheet. 1994 Dec 5;4.
47. Ferguson JH. NIH consensus conferences dissemination and impact. Ann NY Acad Sci 1993;703:180.
48. Maly RC, Abrahamse AF, Hirsch SH, et al. What influences physician practice behavior? An interview study of physicians who received consultative geriatric assessment recommendations. Arch Fam Med 1996;5:448.
49. Penston JG. Helicobacter pylori eradication-understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;9:85. Letter.
50. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA 1996;276:1135. Letter to the editor.
51. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493.
52. Glupczynski Y, Labbé M, Van der linden MP, et al. Lack of antibiotic compliance in patients treated for Campylobacter pylori-associated gastritis. Am J Gastroenterol 1989;84:1126. Letter.
53. Malfertheiner P. Compliance, adverse events, and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 1993;28 Suppl 196:34.
54. Axon ATR. Helicobacter pylori therapy: Effect on peptic ulcer disease. J Gastroenterol Hepatol 1991;6:131.
55. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am J Gastroenterol 1990;85:1545.
56. Glupczynski Y, Labbé M, Burette A, et al. Treatment failure of ofloxacin in Campylobacter pyloridis infection. Lancet 1987;1:1096. Letter.
57. Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: Clinical and in vitro studies. J Clin Pathol 1988;41:207.
58. Becx MC, Janssen AJ, Clasener H, et al. Metronidazole-resistant Helicobacter pylori. Lancet 1990;1:539. Letter.
59. Glupczynski Y, Burette A, De Koster A, et al. Epidemiological factors associated with metronidazole resistance in Helicobacter pylori. Lancet 1990;1:976. Letter.
60. Glupczynski Y, Burette A. Failure of azythromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol 1990;85:98. Letter.
61. Hentschel E, Brandstatter G, Dragosics B, et al. Effects of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308.
62. Rokkas T, Karameris A, Mavrogeorgis A, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer. Gastrointest Endosc 1995;42:1.
63. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994;55:19.
64. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc 1990;36:S8.
65. Imperiale TF, Speroff T, Cebul RD, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Int Med 1995;123:665.
66. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257.
67. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665.
68. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735.
69. Bloom BS, Fox NA, Jacobs J. Patterns of care and expenditures by California Medicaid for peptic ulcer and other acid-related diseases. J Clin Gasteroenterol 1989;11:615.
70. Health and Public Policy Committee. American College of Physicians. Endoscopy in the evaluation of dyspepsia. Ann Intern Med 1985;102:266.